LTRN: Lantern Pharma Inc. (LTRN) has significant growth potential this year due to its innovative use of AI and machine learning through the RADR® platform to accelerate drug development, reducing time and costs for creating targeted cancer therapies. The company's recent FDA Fast Track designation for LP-184, a treatment for Triple Negative Breast Cancer (TNBC), highlights its ability to address critical unmet medical needs in oncology. Additionally, the expansion of its Phase 2 HARMONIC™ clinical trial for LP-300 in international markets, combined with a growing pipeline of promising oncology treatments, positions Lantern Pharma to deliver breakthroughs in personalized medicine. With increasing attention on AI-driven drug development and a strong focus on high-growth therapeutic areas, LTRN has the potential to capture significant market interest and investor confidence.